echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Over 6 drug reviews since March!

    Over 6 drug reviews since March!

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On March 5, Yabao Pharmaceutical announced that the company has recently received an approval notice issued by the State Food and Drug Administration, and the company's methylcobalamin injection has passed the quality and efficacy consistency evaluation of generic drugs
    .
    As of the announcement date, the company's methylcobalamin injection research and development project has invested about 8.
    3002 million yuan in research and development
    .
    The announcement shows that methylcobalamin injection is mainly used for the treatment of peripheral neuropathy and macrocytic anemia caused by lack of vitamin B12
    .
    According to statistics from Minei, the sales amount of methylcobalamin injection in China's public medical market in 2020 is 488 million yuan
    .
    In 2021, the company's sales revenue of methylcobalamin injection will be 670,400 yuan
    .
    Up to now, including the original research company, a total of 24 domestic manufacturers have obtained the approval for the production of methylcobalamin injection, and 3 companies have passed the evaluation
    .
    In addition to Yabao Pharmaceutical's methylcobalamin injection, the author learned that since March, there have been good news from a number of pharmaceutical companies, involving companies such as Yangzijiang and Wanbangde
    .
    On March 3, NMPA information showed that Yangzijiang Pharmaceutical's sodium potassium magnesium sulfate oral solution and levofloxacin sodium chloride injection, which were reported as 3/4 generic drugs, were approved for marketing, which were deemed to have passed the consistency evaluation
    .
    According to data from Minet.
    com, the sales of levofloxacin injection in public medical institutions in China in 2020 exceeded 4.
    6 billion yuan
    .
    Previously, the product has been approved for production by 8 local pharmaceutical companies, and it is deemed to have passed the consistency evaluation
    .
    Relatively speaking, the market competition of concentrated solution of magnesium sodium and potassium sulfate for oral administration is good.
    This product is a new type of intestinal cleansing preparation, which has the characteristics of small dosage, high patient tolerance and good intestinal cleansing effect
    .
    Yangzijiang Pharmaceutical's concentrated solution of magnesium, sodium and potassium sulfate for oral administration is the second domestically produced solution after Jichuan Pharmaceutical was approved
    .
    Relevant statistics show that since 2022, 9 drugs of Yangzijiang Pharmaceutical have passed (deemed to pass) the consistency evaluation of generic drugs
    .
    On March 1st, Wanbonde's Phloroglucinol Injection successfully passed the consistency evaluation
    .
    According to data from Minet.
    com, in the first half of 2020, the market size of phloroglucinol in Chinese public medical institutions exceeded 1 billion yuan
    .
    The drug is the first domestic product that has passed the consistency evaluation of generic drugs, which is conducive to improving the market competitiveness of Wanbangde
    .
    The phloroglucinol bulk drug is also one of the company's existing bulk drug products.
    The company stated that it will accelerate the market promotion of phloroglucinol injection by relying on its own production advantages of bulk drug + preparation
    .
    It is worth mentioning that this product is also the third product approved by Wanbangde Pharmaceutical after Bromhexine Hydrochloride Tablets and Clozapine Tablets
    .
    According to incomplete statistics, a total of 6 varieties have passed the consistency evaluation of generic drugs in March.
    In addition to the above varieties, they also include Flunarizine Hydrochloride Capsules from Shanghai Pharmaceuticals and Levobupivacaine Hydrochloride Injection from Osaikang
    .
    Among them, Shanghai Pharmaceuticals is the second company that has passed the review of Flunarizine Hydrochloride Capsules in China
    .
    According to relevant national policies, the quality and efficacy of the over-evaluated drugs are equivalent to the original products, and appropriate support will be given in terms of medical insurance payment and procurement by medical institutions
    .
    For pharmaceutical companies, product review is good news, which is conducive to enhancing the company's market competitiveness and expanding market share
    .
    However, it also needs to be noted that the market competition for some varieties has been very fierce, with more than 3 companies that have been reviewed, and some companies that have been reviewed are even approaching 10
    .
    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.